<DOC>
	<DOCNO>NCT00253344</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving lenalidomide together docetaxel may kill tumor cell . PURPOSE : This phase I trial study side effect best dose lenalidomide give together docetaxel treat patient advance solid tumor .</brief_summary>
	<brief_title>Lenalidomide Docetaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose lenalidomide give combination docetaxel patient advance solid tumor . Secondary - Determine safety regimen patient . - Determine objective tumor response patient treat regimen . - Determine time progression patient treat regimen . OUTLINE : This multicenter , dose-escalation study lenalidomide . Patients receive oral lenalidomide day 1-14 docetaxel IV 1 hour day 1 . Courses repeat every 21 day disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos lenalidomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Advanced disease Refractory standard therapy OR standard therapy exist Measurable evaluable disease No active brain metastasis Previously treat ( e.g. , surgery radiotherapy ) brain metastasis allow provide currently asymptomatic inactive CT scan MRI PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy At least 4 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8 g/dL Hepatic Bilirubin normal Meets 1 follow criterion : Alkaline phosphatase ( AP ) normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal Renal Creatinine ≤ 2 mg/dL Cardiovascular No New York Heart Association class III IV heart disease Immunologic No prior desquamate rash ≥ grade 2 allergic reaction receive thalidomide No history hypersensitivity docetaxel drug formulate polysorbate 80 No history allergic reaction compound similar chemical biologic composition study drug Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled illness condition would preclude study compliance No peripheral neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent hematopoietic growth factor course 1 study treatment No concurrent immunotherapy Chemotherapy At least 6 week since prior mitomycin nitrosoureas No 2 prior course mitomycin No concurrent chemotherapy Radiotherapy No prior pelvic radiotherapy Other At least 4 week since prior anticancer therapy No concurrent warfarin anticoagulation ( heparin allow ) Recovered prior treatment No concurrent anticancer therapy except bisphosphonates No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>